Inflammasome: a new trigger of Alzheimer's disease

Current therapies are primarily indicated for symptomatic control, but they do not have the capacity to inhibit or lead to regression of the pathologic changes contributing to Alzheimer's disease. [...]current research into this condition is primarily focused on developing targeted therapies ag...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in aging neuroscience Vol. 6; p. 80
Main Authors Saco, Tara, Parthasarathy, Prasanna T, Cho, Young, Lockey, Richard F, Kolliputi, Narasaiah
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Research Foundation 06.05.2014
Frontiers Media S.A
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Current therapies are primarily indicated for symptomatic control, but they do not have the capacity to inhibit or lead to regression of the pathologic changes contributing to Alzheimer's disease. [...]current research into this condition is primarily focused on developing targeted therapies against genes involved in the development of Alzheimer's disease. [...]it is also well known that inflammatory cytokines inhibit microglial phagocytosis. [...]Heneka et al. suggested that the NLRP3 inflammasome contributes to ineffective microglial phagocytosis by leading to increased expression of inflammatory cytokines. The authors also suggest that activation of NLRP3 enhances Alzheimer's disease and may be involved in synaptic dysfunction, cognitive impairment, and the restriction of microglial clearance functions (Heneka et al., 2013). [...]human trials should be conducted to determine the validity of this hypothesis.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Edited by: Fernanda Laezza, University of Texas Medical Branch, USA
Reviewed by: Fernanda Laezza, University of Texas Medical Branch, USA; Filippo Tempia, University of Turin, Italy
This article was submitted to the journal Frontiers in Aging Neuroscience.
ISSN:1663-4365
1663-4365
DOI:10.3389/fnagi.2014.00080